In this large nationwide cohort study of US veterans with incident IBD, we examined the association of incident TNF inhibitor use with at least 30% decline in eGFR and all-cause mortality and found that incident use (vs non-use) of TNF inhibitors was significantly associated with higher subsequent risk of decline in eGFR but was not associated with risk of all-cause mortality. This evidence concerns the gene TNF and inflammatory bowel disease.